MaxCyte MXCT Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Assay And Other Service Revenue | $2.05M— | $1.97M— | —— | —— | —— | |
| License | $13.22M-13.8% | $12.37M-24.6% | $12.47M— | $12.8M— | $15.33M— | |
| Revenue by Geography | ||||||
| Non Us | $12.63M+6.2% | $11.95M-7.1% | $11.92M+1.8% | $11.94M+9.6% | $11.89M+19.2% | |
| US | $19.66M-23.8% | $21.08M-18.2% | $22.5M-21.2% | $23.81M-24.4% | $25.79M-20.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does MaxCyte break its business down?
- MaxCyte (MXCT) reports revenue by product across 2 parts — Assay And Other Service Revenue and License. Each is extracted from the segment footnotes and tracked over time.
- Where does MaxCyte's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in MaxCyte's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
